| Author | SGLT-2 inhibitor | Age/sex | Ethnicity | Other reported medications | Time from medication administration until pancreatitis | Severity (description) and outcome |
| Patel et al. [14] | Canagliflozin | 71/F | Not specified | Metformin, sitagliptin | 84 days | Necrotizing pancreatitis, resolved | Chowdhary et al. [15] | Canagliflozin | 33/F | African-American | Metformin, levothyroxine | 14 days | Severe acute pancreatitis, resolved | Srivali et al. [16] | Canagliflozin | 50/M | White | Metformin, glyburide | 10 days | Acute pancreatitis precipitating DKA, resolved | Verma [17] | Canagliflozin | 46/F | White | Metformin, insulin, lisinopril, lovastatin, citalopram, estradiol, oxybutynin | 21 days | Moderately severe acute pancreatitis, resolved | Gutch et al. [18] | Dapagliflozin | 48/M | Indian | Metformin | 7 days | Acute pancreatitis precipitating DKA, resolved | McIntire and Bayne [19] | Empagliflozin | 70/M | African-American | Insulin, HCTZ, lisinopril, atenolol, ibuprofen, ranitidine, simvastatin, simethicone | 104 days | Mild pancreatitis, resolved | Lightbourne et al. [20] | Empagliflozin | 52/F | Not specified | Metformin, insulin, furosemide | 30 days | Acute pancreatitis, resolved |
|
|